Bayer Cipro XR
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA approves Bayer's Cipro XR (ciprofloxacin extended-release) Dec. 13 for once-daily treatment of uncomplicated urinary tract infections (UTIs), giving the firm nearly one year to establish the extended-release product before Cipro faces patent expiration in December 2003. The indication was supported by an 891-patient study showing the safety and efficacy of 500 mg Cipro XR to be comparable to conventional 250 mg twice-daily Cipro. An application for complicated UTIs was submitted Oct. 29 (Pharmaceutical Approvals Monthly, Dec. 1, 2002, p. 20). Bayer is highlighting the convenience of the once-daily formulatio
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.